Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety and pharmacokinetics study of NNC0705-0001
NL-OMON60535Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of NNC0705-0001 in cardiometabolic disease, sponsored by Novo Nordisk. Started Jun 2025; status: completed.
02
Drugs
NNC0705-0001
03
Conditions
cardiometabolic disease
Beyond the preview
Go deeper on NL-OMON60535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60535.